Firstly IMU's expenditure for last quarter was $17M and not $20M and secondly Cohort A has been reported as 12 from 6 5 months ago so there's 9 more patients not 3. IMU are clearly behind by around 6-8 months due to the slow efficacy noticed from Cohort A so they combined Azer-Cel with a small dose of IL-2 for Cohort B.
This is why they are opening 5 sites in Australia to catch up and will likely apply for registrational clinical trial end of this year using these data given the FPI in Australia was announced last month so the recruitment here has been relatively quick, those Billboard advertisement seem to be working lol.
IMU Price at posting:
4.3¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)